A statement released earlier today by Zacks Investment Research about Trillium Therapeutics Inc. (NASDAQ:TRIL) bumps the target price to $15.00
- Updated: September 16, 2016
Displaying a price of $13.19, Trillium Therapeutics Inc. (NASDAQ:TRIL) traded 0.15% higher on the day. With the last stock price close up 29.33% from the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. TRIL has been tracking to a 50-day moving average of $11.93 and 200-day average of $10.20. Volume of trade was was down over the average, with 28,322 shares of TRIL changing hands under the typical 68,945 shares.
Reporting a possible upside of 0.14%, Zacks Investment Research bumped the target price of Trillium Therapeutics Inc. (NASDAQ:TRIL) to $15
See Chart Below:
Trillium Therapeutics Inc. has a one-year low of $6.62 and a one-year high of $19.08. The company’s total market value is currently $0.0.
Brief Synopsis On Trillium Therapeutics Inc. (NASDAQ:TRIL)
Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, and Canada.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.